Seattle Genetics Begins Phase I Lymphoma Trial

Seattle Genetics has initiated a second Phase I clinical trial of SGN-35 in patients with Hodgkin lymphoma and other CD30-positive hematologic malignancies.

The Phase I study will initially evaluate escalating single-agent doses of SGN-35 administered weekly to patients with relapsed or refractory CD30-positive hematologic malignancies, including Hodgkin lymphoma. Following the monotherapy portion of the study, the trial will continue with an investigation of SGN-35 in combination with Gemzar (gemcitabine). The trial is expected to enroll up to approximately 40 patients at multiple centers in the US.

Thomas Reynolds, chief medical officer of Seattle Genetics. “During 2008, we are planning to move forward rapidly to define our development pathway for SGN-35, including late-stage clinical trials and registration strategy.”